Regenerative Medicine and Entrepreneurism

EXECUTIVE EDUCATION COURSE
JULY 14-17, 2008

Arnold I. Caplan and Robert D. Hisrich

Faculty

Scott P. Bruder, MD, PhD, BD Corporation
Arnold I. Caplan, Ph.D, Case Western Reserve University
Christopher M. Colburn, Cleveland Clinic Foundation
Caroline Corner, PhD, Pacific Growth Equities, LLC
Robert J. Deans, PhD, Athersys, Inc
Stanton Gerson, MD, Case Western Reserve University
Robert D. Hisrich, MBA, PhD, Thunderbird School of Global Mgmt.
Peter Johnson, PhD, Scintellix, LLC
Christine Kelly, PhD, National Institutes of Health
Caroline Kovac, PhD, Barrill and Company
Steven Livey MD, PhD, Australian Stem Cell Centre
George Muschler, MD, The Cleveland Clinic Foundation
Gail Naughton, PhD, San Diego State University
Brock C. Reeve, MBA, Harvard Stem Cell Institute
Stephen A. Roth, PhD, Immune Control, Inc.
J.B. Silvers, PhD, MSLA, BS, Case Western Reserve University
David S. Smith, JD, Pepper Hamilton, LLP
Elizabeth Sump, BS, Cleveland Clinic Foundation
Cyrus Taylor, PhD, Case Western Reserve University
James R. Tobin, Boston Scientific
Clemens van Blitterswijk, PhD, Twente University, Netherlands
Gary Wnek, MS, MBA, Case Western Reserve University
Robin R. Young, CFA, Robin Young Consulting Group
Regenerative Medicine and Entrepreneurism

Focus

This Executive Education Program will bring together an International Faculty of business managers, government officials, scientists, engineers, physicians, and academicians, who are in the field of Regenerative Medicine to focus on the key economic/business issues (policies and procedures) in this emerging healthcare niche. This focus will be on new business models, new leadership and financing strategies and legal/regulatory hurdles in Regenerative Medicine.

New Models

The Program will help executives understand how entrepreneurial skills can be used both inside (Intrapreneurism) and outside the corporate setting. Scientific and medical innovations must be efficiently translated into business opportunities that both address and meet the patient needs (market demand) and economic realities (local versus global markets). New models and approaches form the experience-based foundations of Regenerative Medicine and provide the focus of this Executive Educational Course. James R. Tobin, the CEO of Boston Scientific and past CEO of Biogen, says:

“I think my perspective might be of some use to people that actually know something about the issues or are motivated to learn them.”

Course Organizers

Arnold I. Caplan and Robert D. Hisrich have lectured worldwide on emerging medical technologies and entrepreneurship in Moscow, Beijing, Switzerland, Capetown, Israel, Boston, Cleveland, Phoenix and other locations. They have set up new companies to deliver new technologies to the marketplace. This Executive Education course in Regenerative Medicine and Entrepreneurism is the first of its kind to introduce new models, new leadership and new financing strategies.

Learning Objectives

The $2 trillion healthcare system is undergoing dramatic changes in both technology and products. Biologic solutions for specific disease states are now replacing inadequate pharma solutions. The new innovative science of Regenerative Medicine requires new levels and avenues of leadership, communication and entrepreneurship. In markets related to quality of life, aging and life-and-death issues, cell-based therapies are emerging that will change the course of healthcare. These new approaches require new business frameworks, new legal and patenting strategies and new global initiatives.

The prime learning objectives will provide exposure to the new scientific and medical logics, the newest economic pricing and marketing models and investment logics that make the traditional big-pharma models obsolete. New leadership and initiatives in government, academia, venture capital and public policy will be discussed on the fabric of entrepreneurial principles (both inside and outside corporations and both in the US and Europe). The crystal ball for the healthcare practices of tomorrow is the global expansion of Regenerative Medicine and Entrepreneurism seen today. The learning objectives involve both understanding and projecting the next wave of innovations and products with roadmaps requiring profitability on a backdrop of creativity and medical innovation. The rising executives of tomorrow are encouraged to join the doers of today.
Arnold Caplan, PhD is Professor of Biology and the Director of the Skeletal Research Center. Dr. Caplan received his PhD from The Johns Hopkins University School of Medicine, Baltimore, Maryland in 1981. He has received the Elizabeth Winston Lanier Award given by the Orthopaedic Research Society, the Marshall R. Urist Award for Excellence in Tissue Regeneration Research, and the Genzyme Lifetime Achievement Award given by the International Cartilage Repair Society in 2007. He has over 330 published manuscripts and 15 issued patents. He founded Osiris Therapeutics, Inc, Cell Targeting, Inc. and also consulting company, aCaBio and has pioneered cell-based therapies in Regenerative Medicine.

Robert D. Hisrich MBA, PhD is the Garvin Professor of Global Entrepreneurship and Director of the Center for Global Entrepreneurship at Thunderbird School of Global Management. He is also president of H&B Associates, a marketing and management consulting firm he founded. Dr. Hisrich received his M.B.A. and Ph.D degrees from the University of Cincinnati and honorary doctorate degrees from Chuvash State University (Russia) and the University of Miskolc (Hungary). He has authored or co-authored twenty-one books including: Global Entrepreneurship, Entrepreneurship: Starting, Developing, and Managing a New Enterprise. He has written over 300 articles on entrepreneurship, international business management and venture capital. Dr. Hisrich has instituted academic and training programs such as the university/industry training program in Hungary, a high school teacher’s entrepreneurship training program in Russia, an Institute of International Entrepreneurship and Management in Russia and an Entrepreneurship Center in China.

Scott P. Bruder, MD, PhD is Senior Vice President and Chief Technology Officer of BD. He is responsible for the corporate strategic planning function, corporate business development, BD Technologies and managing a corporate-wide program to improve the product development process across BD. Prior to BD, Dr. Bruder served as the Worldwide Vice President for Johnson & Johnson Regenerative Therapeutics, LLC. Dr. Bruder is a graduate of the Case Western Reserve University School of Medicine and has a doctorate in stem cell biology. He has 20 issued patents. He has published nearly 150 original articles, book chapters and abstracts in peer-reviewed journals. He is the recipient of the American Academy of Orthopaedic Surgeons’ Kappa Delta Award, the Marshall R. Urist Award from the Association of Bone and Joint Surgeons, as well as the Marshall R. Urist Award for Excellence in Tissue Regeneration Research from the Orthopaedic Research Society.

Christopher M. Coburn is the Cleveland Clinic Foundation’s chief commercialization officer, serving as Executive Director of CCF Innovations. He is a recognized authority on technology commercialization and has consulted, testified and spoken on the subject throughout North America and in 20 countries. He leads a team of nearly two dozen industry veterans. Mr. Coburn serves on the Board of Directors of CleveX, Merlot Therapeutics, PeriTec, Prognostix, and BioEnterprise. He is a former Vice President and General Manager of Battelle Memorial Institute, director of the U.S. Enrichment Corporation (NYSE:USU) and author of numerous articles and book chapters on technology commercialization. He was editor and co-author of Partnerships, the key reference book on public technology commercialization. He served as Ohio’s first Science Advisor, Assistant Director and Deputy Director of the Ohio Department of Development and Executive Director of Ohio’s Thomas Edison Program. He has a Master’s degree from George Washington University.

Caroline V. Corner, PhD is a Senior Research Analyst covering the Regenerative Medicine and Convergent Technologies sectors. Caroline joined Pacific Growth from Montgomery & Co where she was a Vice President and Senior Research Analyst covering medical technology and life sciences companies. Previously, Caroline got her start on Wall Street at Wells Fargo Securities as an Associate Analyst covering medical devices. Prior to working on Wall Street, Caroline was with Baxter Transfusion Technologies in Belgium where she was responsible for supporting the global commercialization of proprietary healthcare technologies and with Eli Lilly working in the protein engineering group. Caroline received her Ph.D. in Biological and Environmental Engineering from Cornell University and her BS in Biological Systems Engineering at Virginia Tech.

Robert J. Deans, PhD is Sr Vice President of Regenerative Medicine at Atherys, Inc. Atherys is developing cell therapeutics for treatment of acute myocardial infarct and adjunctive treatment of allogeneic bone marrow transplant. Dr. Deans has more than 14 years experience in stem cell therapeutics, including 4 years at Osiris Therapeutics as VP of Research. Before joining Osiris in 1998, he was Director of R&D at the Immunotherapy Division of Baxter Healthcare (Nexell Therapeutics), responsible for antibody engineering and development of CD34+ cell selection. Dr. Deans served on the faculty of the Norris Cancer Center at USC Medical School from 1984 to 1992. He received a B.Sc. from MIT in 1973 and a Ph.D. in microbiology from the University of Michigan in 1979 and was a postdoc at UCLA from 1980 to 1984.
Stanton Gerson, MD is the Asa and Patricia Shiverick Professor, Director of the Case Comprehensive Cancer Center, Director of the Ohio Wright Center for Stem Cell and Regenerative Medicine at Case School of Medicine, Cleveland, Ohio. Dr. Gerson is co-editor of the textbook Cancer Gene Therapy. His research interests are in stem cells and DNA repair. He developed the first therapeutic trials of mesenchymal stem cells. He identified mutant MGMT as a drug resistance gene to select for stem cells. He is developing methoxyamine, an inhibitor of base excision repair, for clinical use. Finally, Dr. Gerson uses transgenic mouse models to examine the role of DNA repair in stem cell maintenance.

Peter Johnson, MD is the President and CEO of Scintellix, LLC, a biomedical technology consulting company in Raleigh, NC. Dr. Johnson also serves as Principal, LifeScience Resources for Headway Corporate Resources. He founded and was the first President of the Pittsburgh Tissue Engineering Initiative, and he co-founded and was CEO of TissuInformatics, Inc. He served as CMO, Exec. VP of Life Sciences and CBO of Icoria, Inc. He is a past President of the Plastic Surgery Research Council, the Pennsylvania Biotechnology Association, and the Tissue Engineering Society, International and is presently the Co-Editor-in-Chief of the Journal, Tissue Engineering. He serves on several Boards of Trustees and is Chairman of the Board of medical device company EADevices. He was educated at the University of Notre Dame and the SUNY Upstate Medical University and completed General Surgery and Plastic Surgery residencies at Case Western Reserve University and the University of Pittsburgh with a postdoctoral fellowship in thrombosis biology at Harvard.

Christine A. Kelley, PhD is the Director for the Division of Discovery Science and Technology in the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH). She received her PhD degree in Cell Biology from Boston University in 1988. In 1996 Dr. Kelley became a Program Director in the Vascular Biology Research Group within the Division of Heart and Vascular Diseases in the NHLBI before moving in 1998 to a position as Program Director for Bioengineering within the same Division. Dr. Kelley joined the NIBIB in March 2002 as a Program Director for Bioengineering and assumed her current position as Division Director in May 2003.

Caroline A. Kovac, PhD is Managing Director Burrill & Company. Her role includes the development and execution of investment strategies for leading edge technologies that are contributing to the transformation of medicine and healthcare. These include: personalized medicine, use of IT in healthcare, stem cell research, medical devices and diagnostics and bio-nanotechnology. Prior to joining Burrill, she was GM of the Healthcare and Lifesciences business at IBM, where she led a global team developing the latest IT solutions and services, and oversaw IBM’s investment within the healthcare, pharmaceutical and life sciences markets. She grew the IBM lifesciences business to over $1 billion in revenue in 3 years, making it one of the fastest growing market segments for IBM’s business. She holds a PhD from the Univ. of Southern California and a BA from Oberlin College. She sits on the BOD of Research!America, Africa Harvest and the Foundation for the NIH. She is a trustee of Case Western Reserve Univ. In ’04 was named one of the most powerful women in business by Fortune magazine, and won the Scrip ’05 Pharmaceutical Executive of the Year award.

Stephen Livesey, MD., PhD is CEO of the Australian Stem Cell Centre. He was co-founder and formerly Executive Vice President and Chief Science Officer of LifeCell Corporation, New Jersey USA. Dr. Livesey received his medical degree (M.B.B.S) in 1977 and PhD (MacFarlane Burnett Fellow) in 1985 from the University of Melbourne. In 1986, Dr. Livesey co-founded LifeCell Corporation and in 1991 he became a full-time employee of LifeCell Corporation as Vice President of Scientific Development and in 1993 as Executive Vice President and Chief Science Officer. Dr. Livesey is the inventor of the company’s tissue matrix and cell preservation technology. In 2003, he returned to Australia to join the Australian Stem Cell Centre as the Chief Scientific Officer.

George F. Muschler, MD is an Orthopaedic Surgeon at The Cleveland Clinic Foundation who specializes in arthritis and reconstructive surgery and the treatment of fracture non-unions. He is Vice Chairman of the Department of Biomedical Engineering and Director of the Orthopaedic Research Center. Dr. Muschler is also the Director of the Clinical Tissue Engineering Center which is a collaborative consortium of over 61 investigators at The Cleveland Clinic, Case Western Reserve University, University Hospitals of Cleveland, NASA Glenn Research Center and the Ohio Super Computer. He earned his MD at Northwestern University School of Medicine. He completed his Orthopaedic Surgery residency at the University of Texas Southwestern. He joined the Cleveland Clinic Foundation in 1988. He was elected as an AOA North American Traveling Fellow in 1989 and received a Career Development Award from the OREF in 1990-1992.
Gail K. Naughton, PhD has been the Dean of the College of Business Administration at San Diego State University since August 2002. Prior to that, she founded Advanced Tissue Sciences, where she was the co-inventor of its core technology. Dr. Naughton held a variety of key management positions, including President of ATS and director of the Company. Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd. and Medtronic, raised over $350M from the public market and corporate partnerships and brought four fibroblast-based products from concept through FDA approval and market launch. Dr. Naughton holds over 90 U.S. and foreign patents. Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton founded Histogen in 2007, a regenerative medicine company.

Brock Reeve, MBA graduate of Yale and the Harvard Business School, is Executive Director of the Harvard Stem Cell Institute. Brock comes to Harvard from the commercial sector with extensive experience in both management consulting and operations for technology-based companies with a focus on life sciences. Brock’s business career started with the Boston Consulting Group. Most recently, Brock was COO and Managing Director of Life Science Insights, an IDC company, a consulting and market research firm specializing in information technology in life sciences. Prior to LS1, Brock was an Associate Partner in the Pharmaceutical and Life Sciences practice in IBM’s Business Consulting Services group, working with biotech and pharmaceutical clients on issues ranging from R&D portfolios to operations strategies. Brock also has had hands-on operational responsibility in product management and marketing roles in software start-ups as well as additional experience in IT and the healthcare/life science market as the Healthcare Practice Director at Viant Corp. and a Principal at SRI Consulting.

Stephen A. Roth, PhD is chief executive officer of Immune Control Inc., a drug development company in Conshohocken, PA. Immune Control is testing, clinically (multiple myeloma) and pre-clinically (asthma and rheumatoid arthritis), the role of serotonin in immune cell activation. Prior to Immune Control, Dr. Roth founded Neose Technologies, Inc., in 1990, while a professor of biology at the University of Pennsylvania. He left Penn in 1992 to join Neose, became its chief executive and chairman in 1994, and took Neose public in 1996. Before coming to Penn, where Dr. Roth also served as biology chair from 1982-1987, he was a biology faculty member at The Johns Hopkins University from 1970-1980. He received an A.B. in biology from Johns Hopkins, a Ph.D. in developmental biology from Case Western Reserve University, and did postdoctoral work in carbohydrate biochemistry at Hopkins for three years. Currently, Dr. Roth serves on boards of biotechnology companies, venture firms, and non-profits.

J. B. Silvers, PhD the Elizabeth M. and William C. Treuhaft Professor of Health Systems Management, serves as Faculty Director of the HSMC and holds a joint appointment in Epidemiology and Biostatistics in the Case School of Medicine. Prof. Silvers served as a Commissioner on the Prospective Payment Assessment Commission, as well as other state and federal commissions. He recently joined the board of the Joint Commission on Accreditation of Healthcare Organizations. Dr. Silvers research in the areas of financial management and health services has been published in the Journal of Finance, the Journal of the American Medical Association, Health Services Research and many others. Recent work deals with the growth hormone market and decisions to initiate and end treatment, merger and acquisition activity and the impact in health institutions, health insurance, quality and alternative payment methods, capital needs and financing in health care.

David S. Smith, JD is a corporate lawyer focusing on intellectual property transactions, venture financings and regulatory matters for life sciences companies and investors and is of Counsel with Pepper Hamilton LLP, resident in its Pittsburgh office. Mr. Smith’s intellectual property-related work includes IP transactions, regulatory issues and licensing. His corporate practice is concentrated in the organization, financing and growth of life sciences companies. He is an authority on the legal issues surrounding the use of human biological materials and the commercial development of tissue cell and stem cell technologies. Mr. Smith is a founder and principal of Teregemics, LLC. He is an officer of the Tissue Engineering and Regenerative Medicine International Society and the Pittsburgh Tissue Engineering Initiative, Inc.. He is a past member of the board of directors of the Pennsylvania Biotechnology Association.

Elizabeth Sump, BS is the Executive Director of the Clinical Tissue Engineering Center (CTEC) and maintains a leadership role in ensuring translation of technologies developed by this State of Ohio-funded initiative. Ms. Sump currently maintains the Commercialization Council for CTEC and serves on the Commercialization Council for CSCRM, its sister organization. Ms. Sump is a seasoned product development and business development executive with experience in technology licensing through CCF Innovations, the Cleveland Clinic technology transfer office. Prior to her work with the Cleveland Clinic, Ms. Sump served as Vice President of Business and Corporate Development for NetGenics Inc. (a biotechnology company, later acquired by LION Bioscience Inc), where she was responsible for business development, equity financing transactions and licensing. Ms. Sump has an additional seven years experience in product and brand management in the research products market.
James R. Tobin, MBA joined Boston Scientific as President and CEO in 1999. With approximately 27,500 employees worldwide, the company develops, manufactures and markets medical devices for use in a broad range of interventional medical specialties. Before joining Boston Scientific, Mr. Tobin was President and CEO of Biogen, Inc. He joined Biogen as President and COO in 1994 and became President and CEO in 1997. He also served on the company’s Board of Directors. Mr. Tobin spent 22 years with Baxter International, rising from Financial Analyst to President and COO. He served as President and COO of the 60,000 employee, $9 billion company from 1992 until 1994. Mr. Tobin serves on the boards of Boston Scientific Corporation, Appliedera Corporation, Curis, Inc., and is involved with the BioMedical Science Career Program and the New England Conservatory. He also served as lieutenant in the U.S. Navy from 1968 to 1972. He holds an A.B. and an M.B.A. from Harvard.

Clemens van Blitterswijk, PhD is full Professor at the department of Tissue Regeneration at the University of Twente, The Netherlands. His group, one of the prominent tissue engineering groups in Europe, focuses on musculoskeletal tissue engineering. Commercialization of the technologies is an important motivation for the researchers at the department. In the past, this has led to several university spin-off’s like CAM Implants and IsoTis. More recently new ventures have been started such as Progentix and Cellotec. Clemens van Blitterswijk was co-founder and functioned as CEO of IsoTis for 6 years, during which period it was started and went public.

Gary Wnek, MS, MBA, PhD is the Joseph F. Toot, Jr., Professor of Engineering, Chairman of the Department of Macromolecular Science and Engineering, and Faculty Director of The Institute for Management and Engineering at Case Western Reserve University. He received his PhD in Polymer Science and Engineering from the University of Massachusetts, Amherst, and has been a faculty member at MIT (Materials Science and Engineering), RPI (Chemistry) and VCU (Chemical Engineering). Gary’s research interests include multifunctional polymer micro- and nanofiber scaffolds for regenerative medicine with particular recent interest in retina and cornea repair, microfluidic devices, polymers for applications in the energy sector and polymer product design. He has helped to launch three start-ups in the polymeric biomaterials area.

Robin R. Young, CFA is founder and president of RRY Publications and Robin Young Consulting Group, a firm specializing in evaluating and promoting orthopedic technologies and companies. Mr. Young is an internationally recognized expert in his field, with over two decades of experience. Over the course of his career, he has been an active and integral part of the development, analysis and funding of several major orthopedic technologies including; spine cages, engineered allograft, living cell biomaterials, anti-adhesives, third generation hemostats, calcium based bone void products, nucleus replacement implants and dynamic stabilization implants. After a successful career as one of the leading medical technology analysts on Wall Street, he was instrumental in forming and managing the Healthpoint Capital research and private equity practice. In concert with HealthpointCapital, Mr. Young wrote three highly acclaimed orthopedic industry reference books, “Dynamic Stabilization Workbook-2004”, “Biomaterials Industry Outlook-2004” and the “Spine Industry Workbook-2003”. 
Monday, July 14 – Session 1: Regenerative Medicine

1:00-1:15 p.m.: Introduction - Arnold Caplan, PhD/Robert Hisrich, MBA, PhD

1:15-3:00 p.m.: “Regenerative Medicine: What is it? Where did it arise from? Where is it going?” Arnold Caplan, PhD, Case Western Reserve University

3:00-3:30 p.m.: Break

3:30-4:30 p.m.: “Regenerative Medicine in Orthopaedics” George Muschler, MD, Cleveland Clinic Foundation

4:30-5:30 p.m.: “Regenerative Medicine in Cardiology” James Tobin, President and CEO Boston Scientific

6:00 p.m. - Dinner Provided

7:30 p.m.: “Entrepreneurism/Intrapreneurism” Robert Hisrich, MBA, PhD, Thunderbird School of Global Management

Tuesday, July 15 – Session 2: Business Models

8:15-9:45 a.m.: “Principles of Business Modeling” Robin Young, CFA, Robin Young Consulting Group

9:45-10:00 a.m. - Break

10:00-11:15 a.m.: “The Pharma Model that Doesn’t Work; The Tissue Engineering Model that Failed” Gail Naughton, PhD, Dean, San Diego State University

11:15-12:30 p.m.: “Application Model: Vision for the Future” Scott P. Bruder, Senior Vice President and Chief Technical Officer, Becton, Dickenson Corporation

12:30-1:30 p.m. - Lunch Provided

Session 3: New Leadership in Regenerative Medicine

1:30-3:00 p.m.: “The Role of Educational Institutions” Panel with representatives from Schools of Management, Engineering, Medicine, and Arts and Sciences. J.B. Silvers, School of Management; Gary Wnek, MS, MBA, PhD, School of Engineering; Stanton Gerson, MD, School of Medicine; Cyrus Taylor, PhD, Dean College of Arts and Sciences; Gail Naughton, PhD, Dean, Business School San Diego State.

3:00-3:15 p.m. - Break

3:15-4:15 p.m.: “From the Clinic to Academics to Business and Back to the Clinic” Peter Johnson, PhD, President and CEO, Scintellix, LLC

4:15-5:15 p.m.: “The Serial Entrepreneur” Stephen Roth, PhD, CEO, Immune Control, Inc.

5:15-6:00 p.m.: “Entrepreneurism / Intrapreneurism Regenerative Medicine Problem Set”

6:00 p.m. - Dinner Not Provided
Wednesday July 16 – Session 4: New Financing Strategies

8:15-9:45 a.m.: “Financial Strategies for Regenerative Medicine” Caroline Kovac, PhD, Burrill and Company

9:45-10:00 a.m. - Break

10:00-12:30 p.m.: Panel (30 minute lecture each, 1 hr Q&A)

“Pharma Buys Its Pipeline: Acquisitions” Caroline Corner, PhD, Pacific Growth Equities, LLC
“Venture Financing Requires New Entities and Involves Unique Risks: The Isotis Story” Clemens van Blitterswijk, PhD, Twente University, Netherlands
“Backing into the Public Markets: Radius Venture and Athersys” Robert Deans, PhD, Senior Vice President Athersys, Inc.

11:30 am-12:30 pm: Question and Answer

12:30-1:30 p.m. - Lunch Provided

Session 5: Financing Strategies

1:30-2:30 p.m.: “Federal Government Funding Cycles as Related to Technology Development: NIH” Christine Kelly, PhD, National Institutes of Health

2:30-5:30 p.m.: Public/Private: New Avenues (30 minute each)

“Private Philanthropy” Brock Reeve, MBA, Harvard Stem Cell Institute
“International Models: The Australian Stem Cell Center” Steven Livesey, MD, PhD, CEO Australian Stem Cell Institute
“Local Government: Ohio’s Third Frontier Program” Elizabeth Sump, BS, Cleveland Clinic Foundation
“Good News, Bad News: Christopher Coburn, Cleveland Clinic Foundation

5:30-6:30 p.m.: Group Reports for Regenerative Medicine Problem Set

7:00 p.m.: Dinner Provided and Speaker TBA

Thursday, July 17 – Session 6: Hurdles for Regenerative Medicine (Legal and Regulatory, and Intrapreneurism)

8:30-9:45 a.m.: “Legal Environment: Patents, Timing, and Risk” David Smith, JD, Pepper Hamilton, LLP

9:45-10:00 a.m. - Break

10:00-11:00 a.m.: “FDA: Cell-Therapy and Regenerative Medicine From Inside The Panel” Stanton Gerson, MD, Case Western Reserve University

11:00-12:00 noon: “New Concepts/Principles of Intrapreneurism” Robert Hisrich, MBA, PhD, Thunderbird School of Global Management

12:00-12:30 p.m.: “Summation/Conference Conclusion” Arnold Caplan, PhD, Case Western Reserve University

12:30 p.m. - Lunch Provided/Departure
Marketing Targets: Executives from Corporations, Government, Academics

Core Faculty: Arnold Caplan PhD.; Robert Hisrich, MBA, PhD

Tuition: $5,500 (10% discount for CWRU and Thunderbird Alumni); Early Registration $4,500.

Lectures/Lunches: Management School: Peter B. Lewis Building

Housing: Block of Rooms at the Glidden House ($139 single, $139 double has been set aside)

Glidden House Inn,
1901 Ford Drive, Cleveland, OH 44106
216-231-8900 or go to www.gliddenhouse.com

Applicants should make their own arrangements. To receive the special rate, you must identify yourself as a Regenerative Medicine group member.

[Housing, Transportation: Registrants’ Responsibility]
REGISTRATION

To register, complete and mail or fax this form. Checks should be made payable to Case Western Reserve University/Regenerative Medicine and must be mailed to Tammie Lee, Skeletal Research Center, Case Western Reserve University, 2080 Adelbert Road, Cleveland, OH 44106-7080. You may register with a credit card by mail, phone or fax.
Phone: 216-368-3562; Fax: 216-368-4077

REGISTRATION FORM
(Please Print Clearly)

Name/Degree________________________________________
Title_______________________________________________
Company/University__________________________________
Address_____________________________________________
________________________________________________________________________
City________________________________________________
State_________________________________Zip____________
Phone______________________________________________
Fax________________________________________________
Email______________________________________________

Check appropriate box:
☐ I am a member of an endorsing society.
☐ I am a graduate student.
☐ Check enclosed: Amount____________________
☐ Credit Card: ☐ Visa ☐ Master Card
Card Number________________________________________
Card Holder’s Name__________________________________
Billing Address_______________________________________
________________________________________________________________________
Expiration Date______________________________________
Amount_____________________________________________

Card Holder’s Signature______________________________

REFUND POLICY: All refund requests must be made in writing. Full refunds will be given for cancellations received by June 27, 2008. Cancellations received June 30, 2008 through July 8, 2008 will be subject to a $500 cancellation fee. No refunds will be given after July 9, 2008.

Case Western Reserve University
Skeletal Research Center
Biology Department
2080 Adelbert Road
Cleveland, OH 44106-7080
Administrator: Tammie Lee
E-mail: tammie.lee@case.edu
Phone: 216-368-3562
Fax: 216-368-4077